Skip to content

How can we treat photophobia in migraine? A functional imaging investigation of two opposing concepts

How can we treat photophobia in migraine? A functional imaging investigation of two opposing concepts

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00007739
Enrollment
60
Registered
2015-01-30
Start date
2015-10-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G43.9

Interventions

Group 1: Light Deprivation Condition: Day 0: baseline fMRI Day 1-7: exposition to 1 h complete darkness per day (12.00 – 1.00 p.m.) Day 8: postintervention fMRI Group 2: Light Desensitization Conditi

Sponsors

Universitätsklinik für NeurologieMedizinische Universität Wien
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients: o Migraine without aura according to the criteria of ICHD-III beta o Migraine present on 1 and 4 days per month in the 3 months preceding study inclusion o Intensity of interictal sensitivity to light 2 – 6 on a numeric rating scale with range 0-10 o Intensity of ictal sensitivity to light >4 on a numeric rating scale a numeric rating scale with range 0-10 Controls: o Matched for age, sex, education and socioecomic status to patients o No personal or family history of migraine o sensitivity to light <2 on a numeric rating scale

Exclusion criteria

Exclusion criteria: o Any other recurrent current or previous headache disorder apart from infrequent tension-type headache o Current or previous medication overuse o Pregnancy o Photosensitive epilepsy (excluded by a routine EEG) o Other current or previous brain disorders o Ophthalmological disorders relevant to the study o Psychiatric disorders relevant to the study o Other diseases relevant to the study including circadian rhythm disorders o Regular intake of centrally acting compounds including prophylactic medication for headache in the preceding three months o Shift and / or night work o Regular stay in unusually dark or bright environments o Light therapy within the preceding 3 months o Strategies to avoid exposure to light within the preceding 3 months o Claustrophobia o Metallic implants preventing fMRI o Current or history of substance abuse o Any other fMRI contraindications

Design outcomes

Primary

MeasureTime frame
a. Difference in mean total (i.e. ictal and interictal) sensitivity to light in the week after the intervention (days 8 – 14) between light exposure and light deprivation in patients with migraine b. Change in mean total sensitivity to light in the week after light exposure (days 8 – 14) compared to baseline (days -7 – -1) in patients with migraine c. Change in mean total sensitivity to light in the week after light deprivation (days 8 – 14) compared to baseline (days -7 – -1) in patients with migraine

Secondary

MeasureTime frame
a. Differences in mean interictal and mean ictal sensitivity to light in the week after the intervention (days 8 – 14) between light exposure and light deprivation in patients with migraine b. Changes in mean interictal and mean ictal sensitivity to light in the week after light exposure (days 8 – 14) compared to baseline (days -7 – -1)

Countries

Austria

Contacts

Public ContactRoland Beisteiner

Universitätsklinik für NeurologieMedizinische Universität Wien

roland.beisteiner@meduniwien.ac.at+43 1 40400 34080

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026